Clinical trial · Observational
Fibroblast Activation Protein Inhibitor PET/CT Imaging in Malignant Tumor of Digestive System
The Application of Molecular Probe Targeting Fibroblast Activation Protein in Malignant Tumor of Digestive System
NCT05420558CI-TRIAL-00068027unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this single center prospective study is to assess the value of FAPI PET imaging in predicting early postoperative recurrence of malignant tumor of digestive system and to evaluate the diagnostic performance of FAPI PET/CT in the detection of primary tumor and metastatic lesions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrointestinal Cancer | Malignant Digestive System Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fibroblast activation protein inhibitor PET/CT imaging | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- early postoperative recurrence
- timeFrame
- two years
- description
- Evaluation of the value of FAPI PET imaging in predicting early postoperative recurrence of malignant tumor of digestive system
Secondary outcomes (1)
- measure
- diagnostic performance
- timeFrame
- 18 months
- description
- Evaluation of the diagnostic performance of FAPI PET imaging in detecting malignant tumor of digestive system
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Voluntarily participate and sign the informed consent. 2. Patients with suspected or new diagnosed gastrointestinal cancer or other malignant tumor of digestive system. 3. Complete clinical information, biochemical examination results, CT and/or MRI imaging examination, pathological information, and clinical/imaging follow-up data. Exclusion Criteria: 1. Female patient who plan to become pregnant within 6 months, or pregnant or breast-feeding women. 2. Allergic constitution. 3. Those who are in poor general condition and cannot tolerate PET/CT examination. 4. The researchers believe that he or she is not suitable to participate in this study.
References
Publications (3)
- BACKGROUNDLin R, Lin Z, Chen Z, Zheng S, Zhang J, Zang J, Miao W. [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):2960-2971. doi: 10.1007/s00259-022-05799-5. Epub 2022 Apr 25. PMID 35462566
- BACKGROUNDFu L, Huang S, Wu H, Dong Y, Xie F, Wu R, Zhou K, Tang G, Zhou W. Superiority of [68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT to [18F]FDG PET/CT in delineating the primary tumor and peritoneal metastasis in initial gastric cancer. Eur Radiol. 2022 Sep;32(9):6281-6290. doi: 10.1007/s00330-022-08743-1. Epub 2022 Apr 5. PMID 35380229
- BACKGROUNDQin C, Song Y, Gai Y, Ruan W, Liu Q, Liu F, Zheng D, Zhang P, Liu H, Zhang T, Tao K, Lan X. Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4228-4240. doi: 10.1007/s00259-022-05847-0. Epub 2022 Jun 3. PMID 35657428